Clinical Trials Logo

Filter by:
NCT ID: NCT05939882 Recruiting - Myopia, Progressive Clinical Trials

Low Concentration Atropine in the Prevention of Myopia in Children.

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This double-blind, randomized controlled clinical study is to evaluate the effectiveness and safety of low concentration atropine in preventing myopia in pre-myopia children, and to explore whether there is a dose effect relationship between different concentrations of atropine in preventing myopia.

NCT ID: NCT05939830 Recruiting - Breast Cancer Clinical Trials

Omission of ALND in Breast Cancer Patients With Axillary pCR

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

This prospective, single-arm, phase II trial studies axillary lymph node dissection (ALND) to see if it can be safely omitted in breast cancer patients with axillary pathological complete response (pCR) after neoadjuvant systemic therapy (NST). Breast cancer patients with biopsy-proven positive axillary lymph nodes at initial diagnosis, and converted to negative after NST, which is confirmed by Stained region Lymph Node Biopsy(SrLNB), will be enrolled in the study. In other words, a total of 92 patients will be exempted from ALND after SrLNB, and afterwards complete regional node irradiation (RNI) including the axilla. They will also undergo adjuvant chemotherapy, targeted therapy, endocrinotherapy after surgery. These patients will be followed up in the next three years for local-regional recurrence and long-time survival outcome.

NCT ID: NCT05939778 Recruiting - Rectal Injury Clinical Trials

A Study of TH-SC01 in the Treatment of Radiation-induced Rectal Injury

Start date: September 21, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of allogeneic umbilical cord mesenchymal stem cells in the treatment of radiation-induced rectal injury.

NCT ID: NCT05939648 Active, not recruiting - SARS-CoV-2 Clinical Trials

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled. To evaluate the safety and immunogenicity of the study vaccine in participants aged 18 years and older who have received SARS-CoV-2 Vaccine.

NCT ID: NCT05939596 Active, not recruiting - SARS-CoV-2 Clinical Trials

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Start date: August 10, 2023
Phase: Phase 1
Study type: Interventional

This trial is a phase I clinical trial of a SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo-controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the trial vaccine in participants Aged 18 Years and Older who had received SARS-CoV-2 Vaccine.

NCT ID: NCT05939323 Recruiting - Adolescent Clinical Trials

Correlation Study of Family Communication Disorders and Negative Network Use Behavior Among Adolescents

Start date: July 1, 2023
Phase:
Study type: Observational

The entry point of this project is the social background of the post-epidemic era, with teenagers and parents as the research object, aims to explore the relationship between family communication disorders and adolescent negative network use behavior in the post-epidemic era. This project intends to investigate whether there are family communication disorders and negative Internet use behaviors among 14-25 year old teenagers by issuing questionnaires (sample size: 140). In order to conclude whether there is some connection between family communication disorder and adolescent negative network use behavior.

NCT ID: NCT05939232 Recruiting - Clinical trials for X-linked Adrenoleukodystrophy

Registry of X-linked Adrenoleukodystrophy

Start date: July 20, 2023
Phase:
Study type: Observational [Patient Registry]

This study is a observational study conducted through recruiting X-linked adrenoleukodystrophy (X-ALD) patients, to build a comprehensive evaluation and long-term follow-up platform for X-ALD patients, and to provide a theoretical basis for the treatment and management of X-ALD patients.

NCT ID: NCT05939219 Recruiting - Healthy Volunteers Clinical Trials

Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to evaluate the consistency of the 15-valent pneumococcal conjugate vaccine in three batches of the 3-month-old population, as well as the immunogenicity and safety of vaccination in the 7-5-year-old population

NCT ID: NCT05939193 Recruiting - Acute Kidney Injury Clinical Trials

Effect of Urine-guided Hydration on Acute Kidney Injury After CRS-HIPEC

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

Acute renal injury (AKI) is a common complication after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), and is associated with worse outcomes. Available evidences show that maintaining intraoperative urine output ≥ 200 ml/h by fluid and furosemide administration may reduce the incidence of AKI in patients undergoing cardiopulmonary bypass. The investigators hypothesize that, for patients undergoing CRS-HIPEC, intraoperative urine-volume guided hydration may also reduce the incidence of postoperative AKI.

NCT ID: NCT05939180 Recruiting - Clinical trials for Acute Myeloid Leukemia

VA vs DA for Newly Diagnosed Hig-risk AML

Start date: April 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine Versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (AML) patients with adverse risk featuress. Participants will be 1:1 randomly assigned to the VA and DA groups. Once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. After completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.